Long-term risk of second malignant neoplasm after a cancer in childhood. 1989

F de Vathaire, and O Schweisguth, and C Rodary, and P François, and D Sarrazin, and O Oberlin, and C Hill, and M A Raquin, and A Dutreix, and R Flamant
Département de Statistique Médicale, Institut Gustave Roussy, Villejuif, France.

The risk of subsequent second malignant neoplasm was studied in a cohort of 634 patients, treated for a childhood cancer at the Gustave Roussy Institute between 1942 and 1969, and in complete remission five years after diagnosis. The most frequent types of first primary cancers (FPC) were Wilms' tumours (28% of the children), neuroblastomas (16%), lymphomas (12%) and soft tissue sarcomas (11%). Median follow-up duration after FPC was 19 years. Thirty-two patients (obs = 32) developed a total of 35 second cancers. Bone, thyroid, connective tissues and skin were the most frequent types of second cancer, with six patients for each type. The average annual incidence of second cancer was 0.36%. The average annual incidence for the periods 5-9, 10-14, 15-19, 20-24 and 25+ years after FPC was respectively 0.16%, 0.34%, 0.36%, 0.71% and 1.18%. The cumulative incidence of second cancer for the periods 5-20, 5-25 and 5-30 years after FPC was, respectively, 4.3% (95% CI: 2.8-6.6%), 7.8% (95% CI: 5.1-11.8%) and 13.0% (95% CI: 8.2-20.0%). The expected number of cancers in the cohort, computed from Danish cancer incidence data, was exp = 2.2. When compared to this expected number, the average annual excess incidence of second cancer, defined as obs-exp divided by the number of person years of observation, was 0.33%. This rose from 0.15% for the period 5-9 years after FPC to 1.09% for the period beginning 25 years after FPC. The standardised incidence ratio of second cancer (i.e. obs/exp) was 15 (95% CI: 10-21), and was fairly constant in the period extending from 15 to 20 years after FPC diagnosis. Obs/exp was equal to 25 for the patients who had had chemotherapy and equal to 9 for those who had not. Cyclophosphamide seemed less carcinogenic than the other alkylating agents. Obs/exp was similar for the patients who had received radiotherapy and for those who had not. The risk of cancer increased with age in the reference population and increased faster in the cohort, because the standardised incidence ratio is constant over a long period.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008297 Male Males
D009378 Neoplasms, Multiple Primary Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites. Neoplasms, Synchronous,Neoplasms, Synchronous Multiple Primary,Multiple Primary Neoplasms,Multiple Primary Neoplasms, Synchronous,Synchronous Multiple Primary Neoplasms,Synchronous Neoplasms,Multiple Primary Neoplasm,Neoplasm, Multiple Primary,Neoplasm, Synchronous,Primary Neoplasm, Multiple,Primary Neoplasms, Multiple,Synchronous Neoplasm
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

F de Vathaire, and O Schweisguth, and C Rodary, and P François, and D Sarrazin, and O Oberlin, and C Hill, and M A Raquin, and A Dutreix, and R Flamant
May 2012, Pediatric blood & cancer,
F de Vathaire, and O Schweisguth, and C Rodary, and P François, and D Sarrazin, and O Oberlin, and C Hill, and M A Raquin, and A Dutreix, and R Flamant
November 1996, American journal of surgery,
F de Vathaire, and O Schweisguth, and C Rodary, and P François, and D Sarrazin, and O Oberlin, and C Hill, and M A Raquin, and A Dutreix, and R Flamant
May 2024, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology,
F de Vathaire, and O Schweisguth, and C Rodary, and P François, and D Sarrazin, and O Oberlin, and C Hill, and M A Raquin, and A Dutreix, and R Flamant
August 1994, Ugeskrift for laeger,
F de Vathaire, and O Schweisguth, and C Rodary, and P François, and D Sarrazin, and O Oberlin, and C Hill, and M A Raquin, and A Dutreix, and R Flamant
December 2023, JACC. CardioOncology,
F de Vathaire, and O Schweisguth, and C Rodary, and P François, and D Sarrazin, and O Oberlin, and C Hill, and M A Raquin, and A Dutreix, and R Flamant
December 2003, International journal of cancer,
F de Vathaire, and O Schweisguth, and C Rodary, and P François, and D Sarrazin, and O Oberlin, and C Hill, and M A Raquin, and A Dutreix, and R Flamant
November 2004, British journal of cancer,
F de Vathaire, and O Schweisguth, and C Rodary, and P François, and D Sarrazin, and O Oberlin, and C Hill, and M A Raquin, and A Dutreix, and R Flamant
May 2008, Pediatric blood & cancer,
F de Vathaire, and O Schweisguth, and C Rodary, and P François, and D Sarrazin, and O Oberlin, and C Hill, and M A Raquin, and A Dutreix, and R Flamant
May 2012, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al],
F de Vathaire, and O Schweisguth, and C Rodary, and P François, and D Sarrazin, and O Oberlin, and C Hill, and M A Raquin, and A Dutreix, and R Flamant
January 2007, European journal of cancer (Oxford, England : 1990),
Copied contents to your clipboard!